David Dornan
Vermögen: 1 917 $ am 30.06.2025
Vermögen: 1 917 $ am 30.06.2025
David Dornan currently works at Whitehawk Therapeutics, Inc., as Chief Scientific Officer from 2025.
Dr. Dornan also formerly worked at Gilead Sciences, Inc., as Director & Head-Oncology Research from 2012 to 2017, Bolt Biotherapeutics, Inc., as Senior Vice President-Research & Manufacturing, and Elevation Oncology, Inc., as Chief Scientific Officer from 2022 to 2025.
Dr. Dornan received his doctorate degree from the University Of Dundee and undergraduate degree from the University of Strathclyde.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2025 | 5’223 ( 0.01% ) | 1 917 $ | 30.06.2025 |
| Unternehmen | Position | Beginn |
|---|---|---|
| WHITEHAWK THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 18.02.2025 |
| Unternehmen | Position | Ende |
|---|---|---|
| ELEN ONCO | Technik-/Wissenschafts-/F&E-Leiter | 17.02.2025 |
| BOLT BIOTHERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 11.03.2022 |
| GILEAD SCIENCES, INC. | Direktor/Vorstandsmitglied | 01.11.2017 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | Health Technology |
University Of Dundee
University Of Dundee Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Strathclyde
University of Strathclyde Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage immuno-oncology company | Health Technology |
Elevation Oncology, Inc.
Elevation Oncology, Inc. BiotechnologyHealth Technology Develops elevating precision medicines for cancer treatment | Health Technology |
Aadi Bioscience, Inc.
Aadi Bioscience, Inc. BiotechnologyHealth Technology Develops mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen